×
Do you want to link to this External Site and leave Amgenbd.com?
You will be redirected in 5 seconds.
No, Return to Amgenbd.com
Yes, Leave Amgenbd.com
YOU ARE NOW LEAVING THE AMGENBD WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
An image of DNA structure

2015 Deal Sheet

A select list of transactions announced in 2015 including acquisitions, commercial and development collaborations, out-licensing agreements, equity investments, combination study agreements, spinouts and academic collaborations  

FIRST QUARTER

Kite Pharma
Preclinical cancer immunotherapy collaboration to advance the application of novel Chimeric Antigen Receptor (CAR) T cell therapies

MD Anderson Cancer Center
Preclinical agreement to develop BiTE® therapies for myelodysplastic syndrome

NantCell
Out-license of AMG 479, an anti-IGF-1R antibody previously in Phase 3 development for pancreatic cancer

Celimmune
Out-license and option agreement of AMG 714, an anti-IL-15 antibody in development for certain forms of celiac disease

venBio
Limited partner equity investment managed through Amgen Ventures in venBio limited partnership fund

SECOND QUARTER

Merck
Phase 1b/3 combination study in head and neck cancer with pembrolizumab and talimogene laherparepvec

Precision BioSciences
Amgen Ventures investment in Series A financing of genome editing company

Roche/Genentech
Phase 1b combination study in colorectal cancer and triple negative breast cancer with talimogene laherparepvec and atezolizumab

Acerta Pharma
Equity investment in a biotechnology company pursuing a novel BTK inhibitor for the treatment of certain hematological malignancies and inflammatory disorders

AmBER Program
Amgen program to advance basic biology research with more than 1,000 tools and resources available to academic institutions

Redmile Group
Limited partner investment supported by Amgen Ventures in digital health limited partnership fund

Kezar Life Sciences
Immunoproteasome inhibitor program spun out from Amgen subsidiary Onyx Pharmaceuticals to focus on autoimmune disease

Open Monoclonal Technology
In-license of proprietary human antibody generation platforms known as OmniAb™

THIRD QUARTER

Novartis
Neuroscience collaboration involving Phase 1/2a BACE inhibitor for Alzheimer’s disease as well as AMG 334 and AMG 301 for migraine

Dr. Reddy’s Laboratories
Strategic collaboration to register and market upon approval Amgen's evolocumab, carfilzomib and blinatumomab in India

Xencor
In-license of CD38 bispecific program and multi-target collaboration combining Amgen's proprietary antibodies with Xencor's XmAb® bispecific antibody platform to develop new therapeutic candidates

Dezima Pharma
Acquisition of a cardiovascular company with a Phase 2B oral CETP inhibitor

Tizona Therapeutics
Amgen Ventures investment in Series A financing of preclinical-stage biotechnology company

NantPharma
Out-license of AMG 337, a small molecule inhibitor of c-Met previously in Phase 2 development for gastric and esophageal cancers

Acerta Pharma
Preclinical and clinical collaborations evaluating novel combinations in treating hematological malignancies

FOURTH QUARTER

Merck
Cancer immunotherapy collaboration to support a Phase 1b/3 study of blinatumomab in combination with pembrolizumab in non-Hodgkin lymphoma (NHL)

Merck
Oncology collaboration to support a Phase 1/2 study of AMG 820, Amgen’s anti-colony-stimulating factor 1 receptor (CSF1R) antibody, in combination with pembrolizumab in patients with select advanced solid tumors

GSK
Reacquisition of product rights to denosumab and panitumumab from GSK in 48 countries

Vipergen
Multi-target discovery collaboration using Vipergen’s proprietary DNA-encoded library platform to identify drug candidates across therapeutic areas for selected targets from Amgen

Download a pdf version

©2015 Amgen Inc. All rights reserved. December 2015. This document represents a partial list of transactions in 2015. Some dates listed represent the month the agreement was announced.